

Attorney Docket No. T5986.PCT.US.B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: NATALYA RAPOPORT et )  
al. )  
TITLE: METHOD OF IN VIVO DRUG )  
TARGETING TO SOLID )  
TUMORS VIA )  
ACOUSTICALLY TRIGGERED )  
DRUG DELIVERY IN ) INFORMATION DISCLOSURE  
POLYMERIC MICELLES ) STATEMENT UNDER 37 C.F.R.  
§ 1.97  
SERIAL NO.: 10/722,379 )  
FILED: November 24, 2003 )  
EXAMINER: \_\_\_\_\_ )  
ART UNIT: 1617 )


Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449, which contains a list of patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully invokes the Patent Office's obligation under 37 C.F.R. § 1.97 to consider these references and make them of record in the

Certificate of Deposit Under 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the 12<sup>th</sup> day of March, 2004.

  
Alan J. Howarth  
Attorney Registration No. 36,553

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.K./

above-captioned application. While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously cited by or submitted to the Office, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) that was not previously submitted to, or cited by, the Patent Office is also enclosed.

Please charge any additional fees or credit any overpayment to  
Deposit Account No. 50-0836.

DATED this 12<sup>th</sup> day of March, 2004.

Respectfully submitted,



Alan J. Howarth  
Attorney Registration No. 36,553

CLAYTON, HOWARTH & CANNON, P.C.  
P.O. Box 1909  
Sandy, UT 84091  
Telephone: (801) 255-5335  
Facsimile: (801) 255-5338

AJH/kdl

S:\CHC Files\T 5--\T5986\PCT\US\B\ids.wpd



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
T5986.PCT.US.B

SERIAL NO. 10/722,379

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT Natalya Rapoport et al.

FILING DATE November 24, 2003

GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,182,330	Jan. 8, 1980	Michaels			
	AB	5,190,766	Mar. 2, 1993	Ishihara			
	AC	5,267,985	Dec. 7, 1993	Shimada et al.			
	AD	5,421,816	Jun. 6, 1995	Lipkovker			
	AE	5,441,745	Aug. 15, 1995	Presant et al.			
	AF	5,445,611	Aug. 29, 1995	Eppstein et al.			
	AG	5,580,575	Dec. 3, 1996	Unger et al.			
	AH	5,614,502	Mar. 25, 1997	Flotte et al.			
	AI	5,698,529	Dec. 16, 1997	Alakhov et al.			
	AJ	5,795,581	Aug. 18, 1998	Segalman et al.			
	AK	5,830,430	Nov. 3, 1998	Unger et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
X	AL	WO 07/07734	Mar. 6, 1997	PCT				

OTHER PRIOR ART (Including Author, Title, Volume and/or Name of Publication, Relevant Pages and Date [as available])

X	AM		Batakhova et al., Anthracycline Antibiotics Non-covalently Incorporated into the Block Copolymer Micelles: <i>In Vivo</i> Evaluation of Anti-Cancer Activity, 74 Br. J. Cancer 1545-1552 (1996)					
X	AN		Dunn et al., Polystyrene-poly(ethylene glycol) (PS-PEG3000) Particles as Model Systems for Site Specific Drug Delivery. 2. The Effect of PEG Surface Density on the In-Vitro Cell Interaction and In-Vitro Biodistribution, 11 Pharm. Res. 1016-1022 (1994)					
X	AO		Kwon et al., Block Copolymer Micelles as Vehicles for Hydrophobic Drugs, 2 Colloids and Surfaces B: Biointerface 420-434 (1994).					

EXAMINER /Luke Karpinski/

DATE CONSIDERED 02/12/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

X Did not receive

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.K./

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. T5986.PCT.US.B		SERIAL NO. 10/722,379	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>				APPLICANT Natalya Rapoport et al.			
				FILING DATE November 24, 2003		GROUP 1617	

U.S. PATENT DOCUMENTS							
EXAMINER INITIALS	AP	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AP	6,022,316	Feb. 8, 200	Eppstein et al.			

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Volume and/or Name of Publication, Relevant Pages and Date [as available])		
X	AQ	Kwon et al., Physical Entrapment of Adriamycin in AB Block Copolymer Micelles, 12 Pharmaceutical Research 192-196 (1995)
X	AR	Kwon et al., Biodistribution of Micelle-forming Polymer-drug Conjugates, 10 Pharm. Res. 070-074 (1993)
X	AS	Kwon et al., Micelles Based on AB Block Copolymers of Poly(ethylene oxide) and Poly(D-benzyl L-aspartate), 0 Langmuir 045-049 (1993)

EXAMINER /Luke Karpinski/	DATE CONSIDERED 02/12/2008
---------------------------	----------------------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Did not receive

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.K./

[illegible]

\* Did not receive

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.K./

✓	AW	Yokoyama et al., Toxicity and Antitumor Activity against Solid Tumors of Micelle-forming Polymeric Anticancer drug and Its Extremely Long Circulation in Blood, 51 Cancer Research 3229-3236 (1991).
	AX	Yokoyama, Polymeric micelles for Drug Delivery: Their Strategy and Perspective, 7 <sup>th</sup> Int'l Symp. on Recent Advantages in Drug Delivery Systems 99-102 (1995).
	AY	Zhang et al., An Investigation of the Antitumor Activity and Biodistribution of Polymeric Micellar Paclitaxel, 40 Cancer Chemother. Pharmacol. 81-86 (1997).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.K./